• Phathom Pharmaceuticals maintained its 2026 net revenue guidance of $310 million to $325 million.
• Operating expense guidance remains $235 million to $245 million, excluding stock-based compensation; gross-to-net discounts are forecast at 55% to 59%.
• Operating profitability is expected for the remainder of the year and the full year, excluding stock-based compensation.
• Cash flow is expected to turn positive in 2027.
• Third-quarter 2026 net revenue reached $84.7 million, up approximately 71% from a year earlier.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.